ロード中...
Hexamethylene bisacetamide impairs NK cell-mediated clearance of acute T lymphoblastic leukemia cells and HIV-1-infected T cells that exit viral latency
The hexamethylene bisacetamide (HMBA) anticancer drug was dismissed due to limited efficacy in leukemic patients but it may re-enter into the clinics in HIV-1 eradication strategies because of its recently disclosed capacity to reactivate latent virus. Here, we investigated the impact of HMBA on the...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6416400/ https://ncbi.nlm.nih.gov/pubmed/30867508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-40760-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|